Clinical trialPhase 1Terminated
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
- Outcome
- Stopped early. Results posted; no analysis attachedPI left institution. (Other)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- December 2009
- Ended
- February 2013
- Enrollment
- 31 participants
- Sites
- 1
- Primary outcomes
- The Optimal Tolerated Regimen of Pazopanib and Ixabepilone When Used in Combination; Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)
- Sponsor type
- Academic / other
- Results posted
- 26 June 2017
- Last update
- 28 December 2017
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 28 December 2017
- Primary outcome
- The Optimal Tolerated Regimen of Pazopanib and Ixabepilone When Used in CombinationAll Arm 1 Participants: 3, n = 22Values: Dose LevelTime frame: Week 3 of each dose levelNo analysis posted for this outcome (outcome 1)
- DLT/MTD
- Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Arm 1: Dose Level 1: 0 of 9Arm 1: Dose Level 2: 3 of 6Arm 1: Dose Level 3: 0 of 3Arm 1: Dose Level 4: 1 of 4Arm 2: Dose Level 3: 2 of 9Values: ParticipantsTime frame: Week 3 of each doseNo analysis posted for this outcome (outcome 2)
- Participants
- Arm 1: Dose Level 1: 9 started, 9 completedArm 1: Dose Level 2: 6 started, 6 completedArm 1: Dose Level 3: 3 started, 3 completedArm 1: Dose Level 4: 4 started, 4 completedArm 2: 9 started, 9 completed
- Serious adverse events
- Dose Level 1: 4 of 9Dose Level 2: 3 of 6Dose Level 3: 7 of 12Dose Level 4: 3 of 4Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
- Number of Participants With Treatment-Related Adverse Events
- Dose Level 1 9/9; Dose Level 2 6/6; Dose Level 3 12/12; Dose Level 4 4/4 [Participants]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.
Detailed description public domain (ClinicalTrials.gov)
Treatment with ixabepilone will be given at an assigned dose as a 3 hour intravenous infusion on day 1 of a 21 day cycle. Treatment with pazopanib will be given at an assigned dose by mouth once a day, beginning on day 1 and continuing daily. Disease assessment will be done every 2 cycles (6 weeks) with treatment continuing until disease progression, unacceptable toxicity or patient refusal.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
The Optimal Tolerated Regimen of Pazopanib and Ixabepilone When Used in Combination [Week 3 of each dose level]. Number, Dose Level. All Arm 1 Participants (n=22): 3.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) [Week 3 of each dose]. Count Of Participants, Participants. Arm 1: Dose Level 1 (n=9): 0; Arm 1: Dose Level 2 (n=6): 3; Arm 1: Dose Level 3 (n=3): 0; Arm 1: Dose Level 4 (n=4): 1; Arm 2: Dose Level 3 (n=9): 2.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Treatment-Related Adverse Events [Up to 30 days post treatment]. Count Of Participants, Participants. Dose Level 1 (n=9): 9; Dose Level 2 (n=6): 6; Dose Level 3 (n=12): 12; Dose Level 4 (n=4): 4.